)
)
)
Trevarx Biomedical, Inc.
Trevarx Biomedical is developing AlphaPARP ([211At]PTT)--the first targeted alpha radiopharmaceutical therapy to reach the DNA where cancer cannot hide. We hope to cure rather than just wound aggressive cancers like ovarian, where 35 women die every day with no effective treatment once relapsed, delivering a revolutionary approach offering unprecedented precision and therapeutic potential in oncology. With compelling scientific results, a validated diagnostic that has imaged over 300+ patients, and strong clinical backing, we are raising $7M Priced Round to fund an IND and University of Pennsylvania Phase 1a trial in 2027. Trevarx is developing a first-in-class breakthrough therapy—poised for $21B markets and rapid pharma exit.
Trevarx Biomedical has a true theronostic platform with PARPTrace ([18F]FTT), a first-in-class PET imaging diagnostic that enables precise patient selection and treatment monitoring for both approved/next-generation PARP inhibitors and AlphaPARP.
Address
PhiladelphiaPennsylvania
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)